Literature DB >> 25712746

Current frontiers in systemic sclerosis pathogenesis.

Marzena Ciechomska1,2, Jacob van Laar1,3, Steven O'Reilly4.   

Abstract

Systemic sclerosis is an autoimmune disease characterised by vascular dysfunction, impaired angiogenesis, inflammation and fibrosis. There is no currently accepted disease-modifying treatment with only autologous stem cell transplant showing clinically meaningful benefit. The lack of treatment options reflects our lack of understanding of the precise molecular mechanisms occurring in the disease. Recent investigations have begun to decipher the molecular pathways underpinning the different aspects of the disease and may provide a rational clinical target(s). Uncovering the molecular mechanisms of the disease is important in understanding systemic sclerosis treatment. The aim of this review was to examine the current thinking in SSc pathogenesis and will offer novel areas for research which may yield novel therapeutics.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  T cells; fibrosis; inflammation; microRNAs; systemic sclerosis

Mesh:

Year:  2015        PMID: 25712746     DOI: 10.1111/exd.12673

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  14 in total

1.  Connective tissue diseases: Nucleosomes and systemic sclerosis.

Authors:  Steven O'Reilly; Jacob M van Laar
Journal:  Nat Rev Rheumatol       Date:  2016-02-04       Impact factor: 20.543

Review 2.  Environmental risk factors of systemic sclerosis.

Authors:  Isabelle Marie; Jean-François Gehanno
Journal:  Semin Immunopathol       Date:  2015-07-04       Impact factor: 9.623

Review 3.  Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.

Authors:  S Kumar; J Singh; S Rattan; A J DiMarino; S Cohen; S A Jimenez
Journal:  Aliment Pharmacol Ther       Date:  2017-02-09       Impact factor: 8.171

4.  Transforming growth factor-β signaling in systemic sclerosis.

Authors:  Nolan B Ayers; Chen-Ming Sun; Shi-You Chen
Journal:  J Biomed Res       Date:  2018-01-18

5.  Dysregulated CD25 and Cytokine Expression by γδ T Cells of Systemic Sclerosis Patients Stimulated With Cardiolipin and Zoledronate.

Authors:  Helena Migalovich Sheikhet; Jose Villacorta Hidalgo; Paul Fisch; Alexandra Balbir-Gurman; Yolanda Braun-Moscovici; Ilan Bank
Journal:  Front Immunol       Date:  2018-04-13       Impact factor: 7.561

6.  Interactions of HLA-DR and Topoisomerase I Epitope Modulated Genetic Risk for Systemic Sclerosis.

Authors:  Sirilak Kongkaew; Thanyada Rungrotmongkol; Chutintorn Punwong; Hiroshi Noguchi; Fujio Takeuchi; Nawee Kungwan; Peter Wolschann; Supot Hannongbua
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

Review 7.  Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis.

Authors:  Chang-Youh Tsai; Song-Chou Hsieh; Tsai-Hung Wu; Ko-Jen Li; Chieh-Yu Shen; Hsien-Tzung Liao; Cheng-Han Wu; Yu-Min Kuo; Cheng-Shiun Lu; Chia-Li Yu
Journal:  Int J Mol Sci       Date:  2020-04-27       Impact factor: 5.923

8.  Identification of Potential ceRNA Network and Patterns of Immune Cell Infiltration in Systemic Sclerosis-Associated Interstitial Lung Disease.

Authors:  Qiuhong Wu; Yang Liu; Yan Xie; Shixiong Wei; Yi Liu
Journal:  Front Cell Dev Biol       Date:  2021-06-17

Review 9.  MicroRNAs Regulating Signaling Pathways: Potential Biomarkers in Systemic Sclerosis.

Authors:  Yisha Li; Jing Huang; Muyao Guo; Xiaoxia Zuo
Journal:  Genomics Proteomics Bioinformatics       Date:  2015-09-11       Impact factor: 7.691

10.  Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis.

Authors:  Percival D Sampaio-Barros; Danieli C O Andrade; Luciana C P Seguro; Sandra G Pasoto; Vilma S T Viana; Ana C M Ribeiro; Nadia E Aikawa; Maria do Carmo S Timenetsky; Alexander R Precioso; Clóvis A Silva; Eloisa Bonfa
Journal:  Rheumatology (Oxford)       Date:  2018-10-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.